Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene therapy technique could aid islet transplants for diabetes, says Pittsburgh study

05.02.2004


Researchers also find current immunosuppression drug therapy may be harmful for transplanted Islets



Treating pancreatic islet cells with a growth factor can dramatically reduce the number of these cells needed for transplants to reverse Type 1 diabetes, according to a study by University of Pittsburgh School of Medicine researchers. In the animal model study, researchers also found that the triple-drug immunosuppression therapy currently used after human islet cell transplants is harmful to transplanted rat pancreatic islets and can actually induce diabetes in rats.

"This study suggests that the current immunosuppression regimen might be further optimized or changed and has potential implications for further improving islet transplant outcomes in humans with Type 1 diabetes," said senior author Andrew Stewart, M.D., chief of the division of endocrinology and metabolism and professor of medicine at the University of Pittsburgh School of Medicine.


The research is published in the February 2004 issue of the journal Endocrinology and on line at http://endo.endojournals.org/.

"On the positive side, by using a rat model that closely mimics events occurring in human islet transplant recipients, we found that introducing a growth factor DNA to pancreatic islet beta cells (the cells that produce insulin) before transplantation induces cell division and greatly enhances the cells’ function and survival," said Dr. Stewart. "That is good news for the 1.6 million people with Type 1 diabetes because the procedure may help surmount difficulties currently posed by the limited availability of human pancreatic islet cells.

"The disappointing news is that we also discovered, much to our surprise, that the three immunosuppressive drugs commonly prescribed for patients after islet cell transplantation induced marked insulin resistance and beta cell toxicity in the models used in our studies, actually inducing diabetes and reducing the function of their new islet cells. This was true even though the doses and the blood levels of the drugs were low and comparable to those used in humans."

In the study, the researchers used a common virus called an adenovirus to deliver hepatocyte growth factor (HGF), which induces beta cell division and prolongs beta cell survival, into pancreatic islets that had been extracted from rat pancreases. Having conducted similar previous research on genetically immunodeficient mice, researchers this time sought to construct a situation that most closely mimics a human islet cell transplant according to the Edmonton protocol. They used an allogenic islet transplant system, using islets from Lewis rats and transplanting them into Sprague Dawley rats (this is similar to transplanting islets from one human donor into a different recipient). They also delivered the islets into the portal vein (as is performed in humans) instead of through a kidney capsule graft (used in their prior studies in mice). Finally, researchers used the standard combination of immunosuppressive drugs – tacrolimus, sirolimus and daclizumab.

After one day, and lasting three weeks, the blood glucose control was far superior in the HGF-treated rats than the controls. Also, the number of islets surviving in the liver in rats that had been transplanted with HGF-treated islets was double that seen with controls, whose transplanted islets had been treated with a control adenovirus. These studies confirmed prior studies from the Pittsburgh group demonstrating the efficacy of HGF in enhancing islet transplant outcomes.

The experiment was then repeated, going beyond three weeks to see if the improvements would be long lasting. As had been observed previously, but this time for 18 weeks, rats whose islets had been pre-treated with HGF maintained blood glucose levels 200 mg/dl lower than the control animals. Since rats live for approximately two years, this could equate to a decade or more in a human.

Surprisingly, however, in control studies, completely normal rats treated with the triple-drug regimen developed markedly increased blood glucose levels, reaching 250 mg/dl in only ten days. In addition, the blood insulin levels increased by three-fold, indicating that these normal rats had become insulin resistant as a result of the triple drug treatment. (Insulin resistance is the cause of Type 2 diabetes, commonly encountered in adults.) In the second, longer study, the control rats all remained diabetic throughout the study and died by week 18 with blood glucose levels in the 400 mg/dl range.

"We have demonstrated that using gene therapy strategies to deliver a growth factor, in this case HGF, to islet cells can improve the efficacy of portal pancreatic islet transplants over the long term using a model of juvenile, or Type 1, diabetes," said Dr. Stewart. "However, the fact that even the non-diabetic, non-transplanted control rats developed severe diabetes with the standard immunosuppressive drug therapy used following human islet cell transplants makes me wonder whether the same might not be occurring in humans, thereby increasing the number of islets needed for successful transplant outcomes and ultimately causing failure of islet grafts. These issues now need to be studied in humans."

"In brief, in my view, the Edmonton protocol for the transplantation of islets is a modern miracle. Our work suggests further optimism: there still may be room for further improvement," Dr. Stewart concluded.

The Edmonton Protocol to treat Type 1 diabetes was developed by researchers at the University of Alberta in Edmonton, Canada. Doctors use ultrasound to guide placement of a small catheter through the upper abdomen and into the liver. Pancreatic islet cells are then injected through the catheter into the liver. In time, islets are established in the liver and begin releasing insulin.


This work was supported by a research grant from the Juvenile Diabetes Research Foundation. The research team was composed of Juan Carlos Lopez-Talavera, M.D., currently at Roche Pharmaceuticals in Nutley, N.J., Adolfo Garcia-Ocana, Ph.D., assistant professor at the University of Pittsburgh School of Medicine, and Irene Cozar Castellano, Ph.D., postdoctoral fellow at the university, and was supported by Karen Takane, Ph.D., research associate at the university and Mr. Ian Sipula, BS, laboratory technician.

CONTACT:
Frank Raczkiewicz
Alan Aldinger
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
RaczkiewiczFA@upmc.edu
AldiAL@upmc.edu

Frank Raczkiewicz | EurekAlert!
Further information:
http://www.upmc.edu/
http://endo.endojournals.org/

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>